TWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome

Çakmak, Burcu Dinçgez; Dündar, Betül; Gencer, Fatma Ketenci; Aydin, Boyama Burcu; Yıldız, Durkadın Elif

doi:10.1080/09513590.2018.1490401

Cited by 17 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, our findings support that patients with PCOS can be followed up using LMR and MHR parameters for cardiovascular risk. Dincgez-Cakmak et al [7], found a significantly higher mean MHR value in PCOS patients compared to the control group (9.6 vs 8.2) and reported a significant relationship between MHR and PCOS for the first time. However, these researchers additionally found that the mean MHR value in PCOS patients with metabolic syndrome was significantly higher than PCOS patients without metabolic syndrome, and stated that MHR value could be used as a predictive marker for metabolic syndrome in PCOS.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Correlation of monocyte/HDL ratio (MHR) with inflammatory parameters in obese patients diagnosed with polycystic ovary syndrome

Herkiloğlu

Gokce

2021

Ginekol Pol

View full text Add to dashboard Cite

Objectives: Monocyte/high density lipprotein (HDL) ratio (MHR) has been reported to be associated with obesity and polycystic ovarian syndrome (PCOS). In this study, it was aimed to evaluate whether there is a relationship between PCOS and MHR and inflammatory parameters, to investigate the relationship level of MHR and lymphocyte/monocyte ratio (LMR), which are easily accessible inflammatory and oxidative stress markers, with obese women with PCOS, and to determine the usability of MHR as a predictive marker for PCOS. Material and methods:The study included 64 PCOS-patients who were admitted to Gynecology clinics and 52 healthy women. Results:The mean MHR (12.5 ± 4.6) in the PCOS group was significantly higher than the control group (10.4 ± 4.0) (p = 0.01). In the examination performed by combining the groups PCOS and obesity status, the mean MHR value in the PCOS-obese group was significantly higher than all the other groups (p = 0.004). In the ROC analysis, the threshold value of 10.1 for MHR was found to have a sensitivity of 84.8% and specificity of 58.5% in determining the association between PCOS and obesity (AUC: 0.721; p < 0.001; LB: 0.628; UB: 0.814; CI 95%). Accordingly, the rate of those with MHR level of 10.1 and above was significantly higher in the PCOS group compared to the control group (67.2% vs 40.4%) (p = 0.001). In the logistic regression analysis, the determination is increased by 3,026 times (odds ratio; 1.401-6.535) in predicting the presence of PCOS in those with MHR value of 10.1 and above, and 7,576 times (Odds ratio; 2.652-21.646) in predicting the presence of PCOS + obesity. was found to be. Correlation analysis in PCOS patients revealed that the MHR value was negatively correlated with age (p = 0.001; r = -0.412), LMR (p = 0.003; r = -0.377), and total cholesterol [p = 0.018; correlation coefficient (r) = -0.302]. Conclusions:This study findings showed that MHR level is significantly related to PCOS, and especially MHR values above 10.1 may be a significant predictive marker for PCOS. Our study findings also show that an association of PCOS and obesity is a very important trigger on MHR.

show abstract

Section: Discussionmentioning

confidence: 91%

“…It has been reported that MHR is associated with metabolic syndrome, obesity and PCOS [7,8]. However, there are very few studies showing a direct relationship between Ginekologia Polska 2021, vol.…”

Section: Introductionmentioning

confidence: 99%

Correlation of monocyte/HDL ratio (MHR) with inflammatory parameters in obese patients diagnosed with polycystic ovary syndrome

Herkiloğlu

Gokce

2021

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…Combining two indicators of opposite changes, MHR is a valuable marker in systemic inflammatory diseases. It is being increasingly recognized as a novel clinically relevant biomarker of pathological inflammation and a new predictor and prognostic factor in cardiovascular disease, cerebrovascular disease, peripheral artery disease, metabolic syndrome, diabetic nephropathy, and multiple sclerosis 23‐31 . Nonetheless rarely has MHR been studied in thyroid disease.…”

Section: Discussionmentioning

confidence: 99%

“…It is being increasingly recognized as a novel clinically relevant biomarker of pathological inflammation and a new predictor and prognostic factor in cardiovascular disease, cerebrovascular disease, peripheral artery disease, metabolic syndrome, diabetic nephropathy, and multiple sclerosis. 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 Nonetheless rarely has MHR been studied in thyroid disease. One large‐scale study reported that MHR level was significantly increased in patients with thyroid nodules; MHR was significantly associated with the presence of thyroid nodule and strongly associated with the presence and size of thyroid nodule irrespective of gender.…”

Section: Discussionmentioning

confidence: 99%

“… 17 , 18 HDL‐C, alone or with the ratio of uric acid (UA), is associated with metabolic syndrome, 19 type 2 diabetes mellitus, 20 thyroiditis, 21 and liver steatosis. 22 MHR is a new biomarker of inflammation and oxidative stress 23 , 24 and is being increasingly recognized as a novel clinically relevant biomarker of pathological inflammation and a new predictor and prognostic factor in cardiovascular disease, 25 , 26 , 27 peripheral artery disease, 28 metabolic syndrome, 29 diabetic nephropathy, 30 and multiple sclerosis. 31 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Monocyte to high‐density lipoprotein cholesterol ratio as an independent risk factor for papillary thyroid carcinoma

Pang

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Papillary thyroid carcinoma (PTC) is considered to be an inflammatory disease. This study aimed to investigate the association of monocyte to high‐density lipoprotein cholesterol ratio (MHR) with PTC. Methods Clinical parameters from 300 patients with PTC and 552 patients with benign thyroid nodule were compared. Serum renal function and liver enzymes, fasting plasma glucose, lipid profile, and blood cell count were measured. Results Patients with PTC had a higher MONO (p < 0.001) and MHR (p < 0.001). There was a step‐wise increase in the prevalence of PTC (p = 0.003) with the tertile of MHR. Logistic regression analysis revealed that MHR could be considered an independent risk factor (p < 0.001) in the case‐control study and the cohort study. Pearson correlation analysis and simple linear regression analysis indicated that MHR was positively associated with neutrophil (NEU) and lymphocyte (LYM) count as well as neutrophil‐to‐lymphocyte ratio (NLR). Area under the curve (AUC) was 0.711. The optimal cutoff of MHR was 0.33 × 109/mmol. Conclusion This study identifies novel evidence that patients with PTC have a higher MHR. MHR is an independent risk factor for PTC. These findings support the application of MHR to predict, diagnose, and evaluate the occurrence of PTC.

show abstract

Association of white blood cell parameters with metabolic syndrome: A systematic review and meta-analysis of 168,000 patients

Mahmood,

Haider,

Samad

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Leukocyte parameters are predicted to be affected in patients with metabolic syndrome (MetS). We conducted a systematic review and meta-analysis to study the association between white blood cell parameters (WBC) in people with and without MetS. Methods: PubMed, EMBASE, Scopus and Cochrane Library databases were searched according to the study protocol. The standardized mean difference (SMD) and 95% confidence intervals (CI) of leukocyte markers between individuals with and without MetS were pooled using an inverse variance model. Additionally, a subgroup analysis by sex was performed where possible. Methodological quality assessment was conducted using the Newcastle-Ottawa scale (NOS) for observational studies and the Cochrane Risk of Bias tool 2.0 for Randomized Controlled Trials (RCTs). Results: Of 6068 articles identified, 63 were eligible for the study. Compared to controls, individuals with MetS showed significantly higher concentrations of total leukocyte count (SMD [95% CI]: 0.60 [0.55–0.65]; P < .00001; I 2 = 100%), neutrophil counts (0.32 [0.28–0.37]; P < .00001; I 2 = 99%), lymphocyte counts (0.15 [0.07–0.23]; P = .0004; I 2 = 100%), basophil counts (0.01 [0.00–0.02]; P = .02; I 2 = 98%), monocyte counts (0.05 [0.02–0.09]; P = .003; I 2 = 99%), and neutrophil-to-lymphocyte ratio (0.24 [0.15–0.33]; P < .00001; I 2 = 98%). There were no significant differences in the eosinophil count (0.02 [−0.01 to 0.05]; P = .19; I 2 = 96%) and monocyte-to-lymphocyte ratio (0.06 [−0.05 to 0.17]; P = .27; I 2 = 100%) between patients with and without MetS, however, the lymphocyte-to-monocyte ratio (0.52 [−0.81 to −0.23]; P = .0005; I 2 = 52%) tended to be significantly lower in patients with MetS. Conclusion: Biomarkers such as total leukocyte count, neutrophil count, lymphocyte count, basophil count, monocyte count and neutrophil-to-lymphocyte ratio are associated with higher levels in patients in MetS and thus can potentially be used for early detection of MetS.

show abstract

TWEAK and monocyte to HDL ratio as a predictor of metabolic syndrome in patients with polycystic ovary syndrome

Cited by 17 publications

References 27 publications

Correlation of monocyte/HDL ratio (MHR) with inflammatory parameters in obese patients diagnosed with polycystic ovary syndrome

Correlation of monocyte/HDL ratio (MHR) with inflammatory parameters in obese patients diagnosed with polycystic ovary syndrome

Monocyte to high‐density lipoprotein cholesterol ratio as an independent risk factor for papillary thyroid carcinoma

Association of white blood cell parameters with metabolic syndrome: A systematic review and meta-analysis of 168,000 patients

Contact Info

Product

Resources

About